Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eric Song

Physician Assistant Colton, CA Physician Assistant

NPI 1083918403 CMS profile 10414375

1850 E Washington St, Colton, CA 92324

Open in the dashboard

General payments

$11,702

409 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Song of Colton, CA is reported in the CMS Open Payments database as having received $11,702 across 409 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $528 25
2024 General $747 45
2023 General $1,274 64
2022 General $1,693 95
2021 General $7,461 180

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Song
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Eric Song were reported at $528. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Eric Song Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $7,461 $132 $37–$438 $132
2022 $1,693 $155 $48–$522 $149
2023 $1,274 $167 $52–$557 $160
2024 $747 $178 $55–$600 $164
2025 $528 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $5,429 46 payments
  2. AbbVie, Inc. $1,278 70 payments
  3. Biodelivery Sciences International, Inc. $995 30 payments
  4. Pfizer Inc. $577 42 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $390 20 payments
  6. Nevro Corp. $324 19 payments
  7. Electronic Waveform Lab, Inc. $261 13 payments
  8. Merck Sharp & Dohme Corporation $221 12 payments
  9. Almatica Pharma LLC $212 36 payments
  10. Arbor Pharmaceuticals, Inc. $211 20 payments
  11. Other $1,805 101 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,109 372 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,913 11 payments
  3. Honoraria $600 1 payment
  4. Grant $42 1 payment
  5. Education $39 24 payments
Products named General payments · program years 2021–2025
  1. EMGALITY $3,387 40 payments
  2. REYVOW $2,042 6 payments
  3. BELBUCA $995 30 payments
  4. UBRELVY $730 29 payments
  5. NURTEC ODT Pain $561 41 payments
  6. QULIPTA $408 33 payments
  7. RELISTOR $390 20 payments
  8. ZAVZPRET $381 27 payments
  9. NURTEC ODT Primary Care $354 21 payments
  10. BOTOX $292 17 payments
  11. Other $2,998 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

905

Median for Physician Assistant: 241

Drug cost

$8,609

Median for Physician Assistant: $4,110

Branded share of claims

21.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 20 $2,588
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 73 $574
Lidocaine Generic 19 $569
Cephalexin Generic 124 $557
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $543
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 42 $445
Albuterol Sulfate Hfa Albuterol Sulfate Brand 14 $367
Gabapentin Generic 36 $313
Ibuprofen Generic 61 $269
Prednisone Generic 116 $268

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$38,248

Of which drugs: $129

Medicare patients

362

Average age 69

Services billed

992

249 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 48%
Diabetes 29%
Ischemic heart disease 23%
Depression 23%
Chronic kidney disease 18%
Heart failure 17%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 60 $20
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 16 180 $13
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 Office 12 12 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $145
$145 — —
ZAVZPRET
  • PFIZER INC. $104
$104 — —
BOTOX
  • AbbVie, Inc. $103
$103 — —
EMGALITY
  • Lilly USA, LLC $102
$102 — —
UBRELVY
  • AbbVie, Inc. $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

409 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record